PACEYES CONJUNCTIVITIS GUIDELINES

PACIFIC EYE CARE SOCIETY (PACEYES) CLINICAL PRACTICE GUIDELINE

IN ASSOCIATION WITH THE PACIFIC EYE INSTITUTE, SUVA, FIJI

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.
1. INTRODUCTION

1.1. Aim
The aim of this guideline is to assist eye doctors and allied eye care providers in the South Pacific region in providing quality treatment for conjunctivitis.

1.2. Disease Definition
Any inflammation that primarily affects the conjunctival area is termed conjunctivitis. It can be infective or non-infective and can be described as acute or chronic.

1.3. Patient Population Definition
Affects individuals in all age group, social strata and both genders equally. Patients usually presents with a red eye with or without discharge.

1.4. Ratings and strength of evidence used in this guideline

**Ratings:** A: Most important, B: Moderately important, C: Relevant but not critical

**Strength of Evidence:** I: Strong, II: Substantial but lacks some of I, III: consensus of expert opinion in absence of evidence for I & II

2. BACKGROUND

2.1. Burden of disease
Conjunctivitis is the commonest complaint for self-referral to the eye clinic. Conjunctivitis is not frequently associated with blindness; however it affects a significant proportion of society suggesting a significant impact on an economy.

2.2. Natural history of disease
The natural history depends on the type of conjunctivitis.

<table>
<thead>
<tr>
<th>Type</th>
<th>Name</th>
<th>Natural History</th>
<th>Possible Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic Conjunctivitis</td>
<td>Seasonal</td>
<td>Seasonal pattern</td>
<td>Eyelid thickening, ptosis, conjunctival scarring, keratitis,</td>
</tr>
<tr>
<td></td>
<td>Vernal/Atopic</td>
<td>Onset in childhood. Chronic course with</td>
<td></td>
</tr>
</tbody>
</table>

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Type</th>
<th>Description</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPC (giant papillary conjunctivitis)</td>
<td>Insidious onset secondary to contact lens wear, exposed suture or prosthesis irritation</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Viral Adenoviral</td>
<td>Self-limiting with duration 5-14 days</td>
<td>Severe cases may have symblepheron, scarring and subepithelial or corneal infiltrates</td>
<td></td>
</tr>
<tr>
<td>Varicella (herpes) Zoster virus (HZV)</td>
<td>Chicken pox in childhood followed by papillary conjunctivitis in reoccurrences</td>
<td>Conjunctival scarring, cicatricial ectropion, dry eye syndrome</td>
<td></td>
</tr>
<tr>
<td>Molluscum contagiosum</td>
<td>Common in adolescents and young adults. Presence of a lid nodule with ipsilateral follicular conjunctivitis</td>
<td>Epithelial keratitis with pannus formation</td>
<td></td>
</tr>
<tr>
<td>Bacterial Simple (nongonococcal)</td>
<td>Self-limiting, may be more severe in children</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Gonococcal in Neonates</td>
<td>Manifests 1-7 days postnatal. May appear later if antibiotic drops used at birth. Rapid evolution with profuse purulent discharge.</td>
<td>Keratitis, corneal perforation, septicemia and meningitis</td>
<td></td>
</tr>
<tr>
<td>Gonococcal in Adults</td>
<td>Rapid onset of profuse purulent discharge</td>
<td>Keratitis, corneal perforation, pelvic inflammatory disease, arthritis</td>
<td></td>
</tr>
<tr>
<td>Chlamydial in Neonates</td>
<td>Manifests 5-19 following birth, may be earlier in premature rupture of membranes, prolonged 3-12 months in untreated cases</td>
<td>Conjunctival scarring, keratitis, Nasopharyngeal, genital or pulmonary infection</td>
<td></td>
</tr>
<tr>
<td>Chlamydial in Adults</td>
<td>Subacute onset with Conjunctival and</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 2.3. Risk factors for disease

The risk of developing conjunctivitis depends on the etiology.

<table>
<thead>
<tr>
<th>Type</th>
<th>Name</th>
<th>Risk factors/predisposing factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic Conjunctivitis</td>
<td>Seasonal</td>
<td>Environmental allergens</td>
</tr>
<tr>
<td></td>
<td>Vernal/Atopic</td>
<td>Hot dry environments, environmental allergens, genetics in atopic</td>
</tr>
<tr>
<td>Mechanical, Irritable, Toxic</td>
<td>Superior limbic keratoconjunctivitis (SLK)</td>
<td>Sub acute onset of symptoms, wax and wane progress</td>
</tr>
<tr>
<td></td>
<td>Pediculosis palpebrarum (Pthirus pubis)</td>
<td>Chronic conjunctivitis with blepharitis</td>
</tr>
<tr>
<td></td>
<td>Contact lens wear</td>
<td>Sub acute onset, resolves slower</td>
</tr>
<tr>
<td></td>
<td>Floppy eyelid syndrome</td>
<td>Presence of floppy eyelids, chronic adult onset</td>
</tr>
<tr>
<td></td>
<td>Medication induced</td>
<td>Gradual onset with continued use of medications</td>
</tr>
<tr>
<td>Immune mediated</td>
<td>Ocular mucus membrane pemphigoid (OMMP)</td>
<td>Onset over age of 60, progressive chronic course</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Sebaceous gland carcinoma</td>
<td>Occurs from 50-90 years of age, rapid progression</td>
</tr>
</tbody>
</table>

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.
<table>
<thead>
<tr>
<th>Category</th>
<th>Example</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPC (giant papillary conjunctivitis)</td>
<td>Contact lens wear, exposed suture on ocular surface</td>
<td></td>
</tr>
<tr>
<td>Viral</td>
<td>Adenoviral</td>
<td>Exposure to infected individuals, concurrent upper respiratory chest infection</td>
</tr>
<tr>
<td></td>
<td>Varicella (herpes) Zoster virus (HZV)</td>
<td>Acute chicken pox, exposure to person with acute chicken pox</td>
</tr>
<tr>
<td></td>
<td>Molluscum contagiosum</td>
<td>Adolescent and young adults, immunocompromised status</td>
</tr>
<tr>
<td>Bacterial</td>
<td>Simple (nongonococcal)</td>
<td>Exposure to infected persons</td>
</tr>
<tr>
<td></td>
<td>Gonococcal in Neonates</td>
<td>Infected parents, exposure to infected persons</td>
</tr>
<tr>
<td></td>
<td>Gonococcal in Adults</td>
<td>Exposure to infected persons</td>
</tr>
<tr>
<td></td>
<td>Chlamydial in Neonates</td>
<td>Infected parents</td>
</tr>
<tr>
<td></td>
<td>Chlamydial in Adults</td>
<td>Exposure to infected persons</td>
</tr>
<tr>
<td>Mechanical, Irritable, Toxic</td>
<td>Superior limbic keratoconjunctivitis (SLK)</td>
<td>Dysthyroid states, female gender</td>
</tr>
<tr>
<td></td>
<td>Pediculosis palpebrarum (Pthirus pubis)</td>
<td>Poor hygiene, sexually transmitted</td>
</tr>
<tr>
<td></td>
<td>Contact lens wear keratoconjunctivitis</td>
<td>Long term use of contact lens</td>
</tr>
<tr>
<td></td>
<td>Floppy eyelid syndrome</td>
<td>Obesity, sleep apnea, upper lid laxity and excursion over lower lid</td>
</tr>
<tr>
<td></td>
<td>Medication induced keratoconjunctivitis</td>
<td>Glaucoma medications, antibiotics, antivirals, others</td>
</tr>
<tr>
<td>Immune mediated</td>
<td>Ocular mucus membrane pemphigoid (OMMP)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>Sebaceous gland carcinoma</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### 2.4. Prevention of Disease

Early detection and treatment is important in preventing complications. The primary prevention measures depend on the etiology.

#### 2.4.1. Infectious Conjunctivitis

- Counsel infected person, their family or colleagues to wash hands and faces frequently and avoid sharing of personal items such as towels.
• Infected individuals instructed to wash hands frequently and to avoid spread by fomites
• Avoid infected persons during contagious period

2.4.2. Ophthalmia neonatorum

• Prenatal screening and treatment of infected mothers
• Use of prophylactic eye drops at birth, recommended are 1% Tetracycline or 2.5% Povidone-iodine

2.4.3. Allergic / Toxic

• Adequate eye protection against some chemicals and toxins

2.4.4. GPC

• Appropriate contact lens care and frequent lens replacement

2.4.5. Universal Procedures

• Ophthalmic staff to adhere to strict hand washing between each patient
• Regular disinfecting of examination surfaces and instruments in the eye clinic
• Adequate sterilization of tonometer head with a 5 minute soak in 70% ethyl ethanol.

3. DIAGNOSIS

3.1. History

3.1.1 Symptoms and signs (A:III)
3.1.2 Duration of symptoms (A:III)
3.1.3 Exacerbating factors (A:III)
3.1.4 Unilateral or bilateral (A:III)
3.1.5 Character of discharge (A:III)
3.1.6 Recent exposure to an infected individual (A:III)
3.1.7 Trauma (mechanical, chemical, ultraviolet) (A:III)
3.1.8 Contact lens wear details (A:III)
3.1.9 Symptoms and signs relating to systemic disease (genitourinary, pulmonary, skin) (A:III)
3.1.10 Allergy, asthma, eczema (A:III)

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.
3.1.11 Use of topical or systemic medications (A:III)
3.1.12 Previous ocular history (B:III)
3.1.13 Compromised immune status (B:III)
3.1.14 Current or prior systemic disease (B:III)
3.1.15 Social history (habits, travel, sexual) (B:III)

3.2. Examination

3.2.1. Visual acuity (A:III)

3.2.2. External examination

3.2.2.1. Regional lymphadenopathy (A:III)
3.2.2.2. Skin (A:III)
3.2.2.3. Abnormality of eyelids and adnexia (A:III)
3.2.2.4. Conjunctiva (pattern, subconj hemorrhage, chemosis, cicatricial change, masses) (A:III)

3.2.3. Slit lamp biomicroscopy

3.2.3.1. Eyelid margins (A:III)
3.2.3.2. Eyelashes (A:III)
3.2.3.3. Lacrimal puncta and canaliculae (B:III)
3.2.3.4. Tarsal and fornical conjunctive (A:III)
3.2.3.4.1. Presence and size of papillae and follicles
3.2.3.4.2. Cicatrical changes, symblepheron
3.2.3.4.3. Membranes and pseudomembranes
3.2.3.4.4. Ulceration, hemorrhages, masses
3.2.3.4.5. Foreign body
3.2.3.4.6. Lid laxity

3.2.4. Bulbar conjunctiva and limbus (A:III)

3.2.5. Cornea (A:III)

3.2.5.1. Epithelial defects
3.2.5.2. Punctuate keratopathy
3.2.5.3. Dendritic keratitis
3.2.5.4. Filaments, ulceration
3.2.5.5. Infiltration, phlictenules
3.2.5.6. Vascularization, keratic precipitates

3.2.6. Anterior chamber (A:III)

3.2.7. Dye staining pattern on conjunctiva and cornea (A:III)

3.3. Investigations

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.
Most conjunctivitis diagnosis can be made from history and examination alone. Additional tests are helpful in some cases; however the presence and reliability of these tests vary between the different clinical settings in the region. Tests that are rarely needed are:

- Cultures (A:I)
- Smears and cytology (A:II)
- Biopsy in suspect of malignancy (A:II)
- Thyroid test in SLK

### 4. MANAGEMENT

Judicious use of medication is required. Dispensing antibiotic eye drops indiscriminately and the use of steroid eye drops in conjunctivitis must be avoided if not specifically recommended. Outlined are the specific approaches for different types of conjunctivitis.

#### 4.1. Seasonal Allergic Conjunctivitis

Non-medical – Avoid / modify sensitizing environments

Medical – Use antihistamines or mast cell stabilizers (A:I)

- Olopatidine (Patanol) guttæ, 1 drop 6 hourly, 1-2 weeks
- Naphazolin/pheniramine (Naphcon) guttæ, 1 drop 6 hourly, 1-2 weeks
- Other antihistamine, mast cell stabilizers, anti-allergy eye medications

#### 4.2. Vernal/ atopic Conjunctivitis

Non-medical - Avoid / modify sensitizing environments

Medical – Use minimal effective Corticosteroid drops (A:III)

- Fluorometholone/ Betamethasone/ Dexamethasone, 1 drop 4-12 hourly, 1-2 weeks

NB: Explain possible complications of steroid drops; check IOP before and after treatment; ensure there is no concurrent conjunctival/corneal infection

#### 4.3. Giant Papillary Conjunctivitis

Non-Medical – Modify / Removing sensitizing factor

Medical – Short course of Corticosteroids according to response (A:III)

NB: Explain possible complications of steroid drops; check IOP before and after treatment; ensure there is no concurrent conjunctival/corneal infection

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.
4.4. **Superior limbic keratoconjunctivitis**

**Non-medical** – Educate patient on Chronicity of disease; thyroid function test

**Medical** - Lubricants, Mast cell stabilizers (Patanol), 1 drop 6-8 hourly; soft contact lenses; temporary punctal occlusion

Filamentary keratopathy – Acetylcystein 10%

4.5. **Contact lens-related keratoconjunctivitis**

**Non-medical** – Discontinue contact lens use for 2 weeks; advise for spectacle use as an alternative

**Medical** – Mild corticosteroids, 1 drop 6 hourly for 2 weeks, add broad spectrum antibiotics such as Chloramphenicol 1 drop 6 hourly with steroids if infection present

4.6. **Floppy eye lid syndrome**

**Non-medical** – Taping lid shut before sleeping; wear protective shield for sleeping; refer for review of sleep apnea

**Medical** – Topical lubricants

**Surgical** – Full thickness upper lid shortening to prevent eversion of upper lid

4.7. **Pediculus Palpebrarum**

**Non-medical** – Patients should be advised on possibility of concomitant disease; refer appropriately; may indicate sexual abuse in children; anti-lice lotion/shampoo use for patients and contacts, avoid use on ocular infestations

**Medical** – Bland ophthalmic ointment (Chloramphenicol/tetracycline) b.d or t.d.s to allow easier removal of nits (eggs) and adult lice

**Mechanical Removal with forceps or by epilation**

4.8. **Medication induced keratoconjunctivitis**

**Non-medical** – Immediate discontinuation of responsible agent

**Medical** – Corticosteroids in presence of severe inflammation

NB: Inflammation usually settles 2 weeks after discontinuation of responsible agent

4.9. **Adenoviral conjunctivitis**
Non-medical – Appropriate measures to reduce risk of transmission as it is highly contagious; cold compresses may help

Medical – There is no antiviral medication for adenovirus. Available antivirals are not effective in adenoviral conjunctivitis. Corticosteroids, antibiotics, artificial tears, topical antihistamines may be used when needed. Fluorometholone (FML) has poor intraocular penetration and is suitable for ocular surface inflammation. It has less effect on IOP

NB: Explain possible complications of steroid drops; check IOP before and after treatment; adenoviral conjunctivitis may take 2-3 weeks for full resolution

### 4.10. Varicella zoster conjunctivitis

Medical – Antivirals are of no benefit, except in immunocompromised patients. Antibiotic eye drops can be given according to severity, to treat secondary bacterial infections.

NB: Check for sequelae as dry eyes, neurotrophic keratitis and corneal anesthesia

### 4.11. Herpes Simplex Virus (HSV) conjunctivitis

Medical - Topical and oral antiviral recommended for prevention of corneal infection. Topical Acyclovir, 1 drop every 4 hours, Oral Acyclovir 200mg – 400mg every 4 hours.

NB: Use of Acyclovir for more than 2 weeks can be toxic. Topical steroid should be avoided. HSV in neonates should be referred to pediatrician.

### 4.12. Molluscum contagiosum

No specific treatment advised. May remove lesion.

### 4.13. Bacterial conjunctivitis

Non-medical – Symptomatic treatment, as condition is self-limiting.

Medical – Broad spectrum antibiotic may shorten duration of condition.

Topical Chloramphenicol 1 drop 2 – 6 hourly or other empirical drug may be used according to severity.

NB: Culture done in severe cases or if Gonococcal is suspected, frequent review until condition is stable (A:I)

### 4.14. Chlamydial and Gonococcal conjunctivitis

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.
Medical – Treatment is orally. Topical empirical antibiotic can be used 2 – 6 hourly until condition improves.

Oral treatment given as:

**Chlamydia in Children** – neonates and children <45kg, Erythromycin 50mg/kg/day in 4 divided doses x 14 days; children >45kg but <8 years, Azithromycin 1g single dose; children >8 years, Azithromycin 1g single dose or Doxycycline 100mg b.d. x 14 days

**Chlamydia in Adults** - Azithromycin 1g single dose or Doxycycline 100mg b.d. x 14 days

**Gonococcal in Children** – neonates, Ceftriaxone 25-50mg/kg IV or IMI, not to exceed 125mg; children <45kg, Ceftriaxone 125mg IMI single dose, or Spectinomycin 40mg/kg, max 2g, for patients allergic to cephalosporin; children >45kg, same as adult dosage.

**Gonococcal in Adults** – Ceftriaxone 1g IMI single dose or Cefixime 400mg oral single dose. Spectinomycin 2g IM single dose in patients allergic to cephalosporin

### 4.15. Trachoma

Non-medical – Facial hygiene, improve sanitation.

**Medical** – Tetracycline ointment application 6 hourly x 2 weeks; Azithromycin 20mg/kg up to 1g single dose

### 4.16. Ocular mucus membrane pemphigoid (OMMP) conjunctivitis

Non-medical – Discontinue any medications causing OMMP

**Medical** – Corticosteroids (topical or oral) to control inflammation; systemic immunosuppressant may be needed to control severe inflammation and prevent progression of scarring, seek local physicians’ advice on immunosuppressive treatment. Treat associated dry eyes, trichiasis, distichiasis and entropion.

### 4.17. Other types of conjunctivitis

Other types refer to chemical, mechanical and conjunctivitis associated with systemic diseases. The underlying cause of conjunctivitis needs to be treated and symptomatic treatment of the eye recommended.
NB: In a setting where the primary eye care provider is not an ophthalmologist, urgent referral to a specialist is required when one of the following is noted:

- Visual loss
- Moderate or severe pain
- Severe, purulent discharge
- Corneal involvement
- Conjunctival scarring
- Treatment failure
- Recurrent episodes
- History of HSV disease
- History of immune compromise

Counseling is imperative in minimizing spread of contagious conjunctivitis.

References


Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.

**Contributors**

1) Dr. John Szetu, Pacific Eye Institute, CWMH, Fiji.
2) Dr. Biu Sikivou, Pacific Eye Institute, CWMH, Fiji.
3) Dr. Konstanz Fischer, Pacific Eye Institute, CWMH, Fiji.
4) Dr. Luisa Cikamatana Rauto, Lautoka Hospital, Fiji.
5) Dr. Anaseini Cama, Pacific Eye Institute, CWMH, Fiji.
6) Dr. Varanisese Rorogasa, Pacific Eye Institute, CWMH, Fiji.
7) Dr. Mundi Qalo, National Referral Hospital, Solomon Islands.
8) Dr. Neil Murray, Fred Hollows Foundation New Zealand.
9) Renee du Toit, Fred Hollows Foundation New Zealand.
10) Dr. Claude Posala, Pacific Eye Institute, CWMH, Fiji.

**Author**

PacEyes clinical guidelines working committee

Pacific Eye Care Society’s Clinical Practice Guidelines – Compiled by Clinical Practice Guidelines working committee 2010 annual PacEYES conference.